See the DrugPatentWatch profile for ezetimibe

The combination of ezetimibe and statins is a common practice in clinical settings to manage and treat high cholesterol levels. Both medications work in different ways to lower cholesterol, providing a synergistic effect when used together.

Ezetimibe is a medication that inhibits the absorption of cholesterol in the intestines, while statins block the production of cholesterol in the liver. By combining these two medications, patients can achieve greater reductions in LDL (low-density lipoprotein) or "bad" cholesterol levels than when using either medication alone [1].

According to DrugPatentWatch.com, the combination of ezetimibe and statins has been proven to be particularly effective in reducing LDL cholesterol levels in patients who have not responded well to statin therapy alone [2]. Additionally, this combination therapy has been shown to reduce the risk of cardiovascular events, such as heart attacks and strokes, in patients with a history of these conditions [3].

Furthermore, the combination of ezetimibe and statins has been found to have a similar safety profile to statin therapy alone, with no significant increase in adverse events or muscle-related side effects [4].

In summary, the combination of ezetimibe and statins offers several benefits for patients with high cholesterol levels, including greater reductions in LDL cholesterol, a lower risk of cardiovascular events, and a similar safety profile to statin therapy alone.

Sources:

1. National Library of Medicine. (2021). Ezetimibe and Simvastatin. <https://medlineplus.gov/druginfo/meds/a607045.html>.
2. DrugPatentWatch.com. (2021). Ezetimibe and Statins. <https://www.drugpatentwatch.com/drugs/ezetimibe-and-statins>.
3. National Lipid Association. (2019). Combination Therapy for Management of Dyslipidemia. <https://www.lipidjournal.com/article/S1933-2874(19)30051-3/fulltext>.
4. National Lipid Association. (2019). Safety and Tolerability of Combination Therapy for Management of Dyslipidemia. <https://www.lipidjournal.com/article/S1933-2874(19)30052-5/fulltext>.